

**Table S3:** Univariate Overall Survival Analysis

Variable	N	Deaths	Median Overall Survival in months(95%CI)	1-year Overall Survival (95%CI)	HR(95%CI)	p-value
<b>Whole Cohort</b>	159	38	Not Reach	89%(82.7-93.1%)		
<b>Age</b> (increase by 5)					1.22(1.03-1.43)	0.02
<b>T<sub>IDS</sub> Delay</b>						
No Delay	125	26	Not Reach	89.7%(82.5-94%)	1	0.01
Delay	34	12	17.2(14.4-Not Estimable)	86%(66.3-94.6%)	2.4(1.2-4.77)	
<b>Stage</b>						
III	50	6	Not Reach	93.6%(81.6-97.9%)	1	0.031
IV	109	32	Not Reach	87%(78.5-92.2%)	2.53(1.06-6.06)	
<b>BRCA</b> (30 missing not included)						
No mutation	101	28	Not Reach	89.3%(81-94.1%)	1	0.041
BRCA mut/VUS	28	3	Not Reach	100%	0.31(0.09-1.02)	
<b>Preoperative Cycles (cont.)</b>					1.26(0.97-1.64)	0.088
<b>Charlson Score</b>					1.25(0.99-1.56)	0.057
<b>Chemotherapy Regimen</b>						
Weekly Paclitaxel + Carboplatin	121	28	Not Reach	93.1%(86.6-96.5%)	1	0.391
Others	38	10	Not Reach	72.9%(52.1-85.8%)	1.37(0.66-2.84)	
<b>Dose Reduction</b>						
No	142	34	Not Reach	88.7%(81.9-93%)	1	0.687
Yes	17	4	20.9(13.7-Not Estimable)	91.7%(53.9-98.8%)	1.24(0.44-3.5)	
<b>Complete Gross Resection</b>						
No	53	20	21.9(18.6-Not Estimable)	78.5%(64.6-87.5%)	1	0.004
Yes	106	18	Not Reach	94.4%(87.1-97.7%)	0.41(0.22-0.77)	
<b>Optimal debulking</b>						
No	20	8	Not Reach	74.1%(48.5-88.3%)	1	0.072
Yes	139	30	Not Reach	91.3%(84.7-95.1%)	0.5(0.23-1.08)	
<b>T<sub>NACT</sub> (Days)</b>					1.01 (1-1.03)	0.106
<b>T<sub>Poc</sub> (Days)**</b>					1.00 (0.97-1.03))	0.898

\* p value is obtained by using Log-rank test for categorical variables and Wald test based on CoxPH model for continuous variables

\*\*Analysis performed using landmark analysis